NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
07 Nov 2017

Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update

Kala Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2017 and provided an update on business progress.
New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting<
25 Oct 2017

New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting

Late-breaking session to highlight Phase 1b clinical trial data for light-activated AU-011 for the treatment of primary ocular melanoma.
25 Oct 2017

Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYSTM (KPI-121 1%)

Kala Pharmaceuticals, Inc. today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration for INVELTYSTM (KPI-121 1%).
Phase 3 prospective/retrospective study of MAFTest® in Lancet Oncology demonstrates the effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer<
19 Oct 2017

Phase 3 prospective/retrospective study of MAFTest® in Lancet Oncology demonstrates the effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer

MAFTest® negative status in patients treated with zoledronic acid in the adjuvant setting was associated with improved invasive-disease-free survival and overall survival.

AELIX Therapeutics appoints Dr. Thomas Hecht as Chairman of the Board of Directors<
18 Oct 2017

AELIX Therapeutics appoints Dr. Thomas Hecht as Chairman of the Board of Directors

Dr. Hecht joins the company as the first patient has been enrolled in the company’s phase I clinical trial for the assessment of its proprietary HTI vaccine.

12 Oct 2017

Dr Bastian Dehmel Appointed CMO of OxThera

OxThera AB, today announced the appointment of Dr Bastian Dehmel as their new Chief Medical Officer.
27 Sep 2017

FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies

Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
25 Sep 2017

Vivet’s First Gene Therapy Product Receives European and US Orphan Drug Designation VTX 801 for Wilson’s Disease

Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product, VTX-801.
AELIX Therapeutics enrolls first patient in company’s initial therapeutic HIV vaccine clinical trial<
06 Sep 2017

AELIX Therapeutics enrolls first patient in company’s initial therapeutic HIV vaccine clinical trial

AELIX-002 phase I study will focus on evaluating the safety and immunogenicity of the HTI vaccine. 
05 Sep 2017

TiGenix obtains commercial production license for expanded manufacturing facility

TiGenix NV announces today that it has obtained a license for the commercial production of expanded adipose-derived stem cells (eASCs) at its expanded manufacturing facility in Madrid.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка